EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A wearable perspiration biosensor for continuous biomarker monitoring in inflammatory bowel disease: Feasibility, concordance, and exploratory temporal dynamics

Annapoorna Ramasubramanya, Kai-Chun Lin, Sarah Shahub, Alexandra R McDermott, Zachary D Fine, Robert P Hirten, Jessica Whang, Drew Helmus, Sriram Muthukumar, Bruce E Sands, David T Rubin, Shalini Prasad

Clinical and Translational Medicine · 2026-11 · 16 (11)

DOI: 10.1002/ctm2.70896 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Medicine, online erschienen am 14.11.2026. Verfasst von Annapoorna Ramasubramanya und 11 weiteren Autor:innen. Beteiligte Einrichtung: Bioengineering, University of Texas at Dallas, Richardson, Texas, USA. Hauptthemen laut MEDLINE: Biomarkers, Inflammatory Bowel Diseases, Wearable Electronic Devices, Biosensing Techniques. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Crohn's and Colitis Foundation Novel Technology Initiative, IBD Ventures Award.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Serum C‐reactive protein (CRP) and faecal calprotectin, used to monitor inflammatory bowel disease (IBD) between endoscopies, require intermittent blood or stool sampling. We assessed whether a skin‐worn perspiration sensor could measure CRP and calprotectin continuously; TNFα and IL‐6 were exploratory analytes.

Methods

At three US centres, perspiration biomarkers were recorded continuously for 3–30 days in 52 IBD patients (27 ulcerative colitis, 24 Crohn's disease, 1 indeterminate colitis) and 19–32 days in 9 controls, with serum CRP and faecal calprotectin sampled at baseline and study end. Agreement was assessed using correlation and Bland–Altman analysis; ROC‐derived cutoffs matched serum CRP 5 mg/L and faecal 250 µg/g. Circadian rhythmicity and ultradian (4–12 h) power were compared among biochemically active IBD (serum CRP > 5 mg/L; n = 15), inactive ( n = 37), and controls.

Results

47 of 52 IBD participants (90.4%) completed the protocol. Across 99 paired observations, perspiration CRP correlated with serum CRP ( r = .52–.58); perspiration and faecal calprotectin correlated in ulcerative colitis ( r = .59–.62) but not in Crohn's disease. A perspiration CRP cutoff of 1551 pg/mL (serum 5 mg/L) gave 85.7% sensitivity and 89.4% specificity; a calprotectin cutoff of 385 (µg/g)·min (faecal 250 µg/g) gave 92.3% and 67.9%. Negative predictive values were high (95%–97%), positive modest (57%). Circadian MESOR and amplitude of both markers were higher in active than inactive IBD. Ultradian power differed by group for calprotectin (Kruskal–Wallis p = .0005) and CRP ( p = .0037)—highest in active disease, lowest in controls—but the active–inactive difference was non‐significant after false‐discovery‐rate correction.

Conclusions

Perspiration CRP agreed moderately with serum CRP, and perspiration calprotectin with faecal calprotectin in ulcerative colitis only. Their high negative predictive values support the study as a non‐invasive adjunct to, not a substitute for, standard‐of‐care testing. All findings are preliminary, and the temporal‐dynamics results are hypothesis‐generating, needing confirmation in a larger, prospectively designed, endoscopy‐anchored cohort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersInflammatory Bowel DiseasesWearable Electronic DevicesBiosensing TechniquesSweatHumansFemaleMaleC-Reactive ProteinAdultLeukocyte L1 Antigen ComplexMiddle AgedFecesFeasibility StudiesMonitoring, Physiologic

Stichwörter der Autor:innen

Crohn's diseasebiomarkersinflammatory bowel diseaseulcerative colitisultradian rhythmwearable devices

Substanzen

BiomarkersC-Reactive ProteinLeukocyte L1 Antigen Complex

Autor:innen und Institutionen

  • Bioengineering, University of Texas at Dallas, Richardson, Texas, USA.
  • The University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, Illinois, USA.
  • The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • EnLiSense LLC, Allen, Texas, USA.

Förderung

  • Crohn's and Colitis Foundation Novel Technology Initiative
  • IBD Ventures Award

Zitieren

APA

Ramasubramanya, A., Lin, K. C., Shahub, S., McDermott, A. R., Fine, Z. D., Hirten, R. P., Whang, J., Helmus, D., Muthukumar, S., Sands, B. E., Rubin, D. T., & Prasad, S. (2026). A wearable perspiration biosensor for continuous biomarker monitoring in inflammatory bowel disease: Feasibility, concordance, and exploratory temporal dynamics. Clinical and Translational Medicine, 16(11). https://doi.org/10.1002/ctm2.70896

Vancouver

Ramasubramanya A, Lin KC, Shahub S, McDermott AR, Fine ZD, Hirten RP, et al. A wearable perspiration biosensor for continuous biomarker monitoring in inflammatory bowel disease: Feasibility, concordance, and exploratory temporal dynamics. Clinical and Translational Medicine. 2026;16(11). doi:10.1002/ctm2.70896

BibTeX
@article{Ramasubramanya2026,
  author = {Ramasubramanya, Annapoorna and Lin, Kai-Chun and Shahub, Sarah and McDermott, Alexandra R and Fine, Zachary D and Hirten, Robert P and Whang, Jessica and Helmus, Drew and Muthukumar, Sriram and Sands, Bruce E and Rubin, David T and Prasad, Shalini},
  title = {A wearable perspiration biosensor for continuous biomarker monitoring in inflammatory bowel disease: Feasibility, concordance, and exploratory temporal dynamics},
  journal = {Clinical and Translational Medicine},
  year = {2026},
  volume = {16},
  number = {11},
  doi = {10.1002/ctm2.70896}
}
Kostenlos starten →